HISTORY OF OUTCOME MEASURES FOR MYASTHENIA GRAVIS

被引：40
|
作者：
Burns, Ted M. [1 ]
机构：
[1] Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA
来源：
MUSCLE & NERVE | 2010年 / 42卷 / 01期
关键词：
myasthenia gravis; outcome measures; MG Composite; MG-QOL15; rating scales; QUALITY-OF-LIFE; SELF-ADMINISTERED QUESTIONNAIRE; ALTERNATE-DAY PREDNISONE; LONG-TERM CORRELATION; MYCOPHENOLATE-MOFETIL; DOUBLE-BLIND; INTRAVENOUS IMMUNOGLOBULIN; ACETYLCHOLINE-RECEPTORS; RANDOMIZED-TRIAL; CLINICAL-TRIAL;
D O I：
10.1002/mus.21713
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
This review illustrates how measurements of clinical status in patients with myasthenia gravis have evolved from clinical descriptions and estimates of mortality rates to more sophisticated evaluative instruments, including numerical rating scales that measure strength, endurance, quality of life, and activities of daily living. The rationale and use of weighting and the importance of patient-reported outcomes are also discussed. The measurement of the steroid-sparing effect of an immunosuppressant is also reviewed. Muscle Nerve 42: 5-13, 2010
引用
收藏
页码：5 / 13
页数：9
相关论文
共 50 条
  • [21] Management of Juvenile Myasthenia Gravis
    O'Connell, Karen
    Ramdas, Sithara
    Palace, Jacqueline
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [22] Myasthenia Gravis Treatment Updates
    CortOs-Vicente, Elena
    Gallardo, Eduard
    Elvarez-Velasco, Rodrigo
    Illa, Isabel
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2020, 22 (08)
  • [23] The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice
    Burns, Ted M.
    MYASTHENIA GRAVIS AND RELATED DISORDERS I, 2012, 1274 : 99 - 106
  • [24] Factors affecting outcome in ocular myasthenia gravis
    Mazzoli, Marco
    Ariatti, Alessandra
    Valzania, Franco
    Kaleci, Shaniko
    Tondelli, Manuela
    Nichelli, Paolo F.
    Galassi, Giuliana
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2018, 128 (01) : 15 - 24
  • [25] FATIGUE IS A RELEVANT OUTCOME IN PATIENTS WITH MYASTHENIA GRAVIS
    Tran, Christopher
    Bril, Vera
    Katzberg, Hans D.
    Barnett, Carolina
    MUSCLE & NERVE, 2018, 58 (02) : 197 - 203
  • [26] Current pharmacotherapeutic options for myasthenia gravis
    Barnett, Carolina
    Tabasinejad, Raha
    Bril, Vera
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (18) : 2295 - 2303
  • [27] Maintenance immunosuppression in myasthenia gravis, an update
    Morren, John
    Li, Yuebing
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 410
  • [28] History of Thymectomy for Myasthenia Gravis
    Cooper, Joel D.
    THORACIC SURGERY CLINICS, 2019, 29 (02) : 151 - +
  • [29] Orphan drugs to treat myasthenia gravis
    Maggi, Lorenzo
    Baggi, Fulvio
    Mantegazza, Renato
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (05): : 373 - 384
  • [30] Antisemitism and the History of Myasthenia Gravis
    Freedman, Stanley
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2010, 12 (04): : 195 - 198
12345